Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BENEFIT study: infliximab in idiopathic pulmonary fibrosis
2004-001876-37Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in idiopathic pulmonary fibrosis (IPF) comparing Infliximab arm with Placebo arm (2 arms). Primary endpoint: Change in FVC from baseline. Started Feb 2007; status: completed.
02
Drugs
infliximab
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on 2004-001876-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-001876-37.